Who
Brian M. Culley
President and CEO
Company insider
Files Form 4 as: President and CEO, Lineage Cell Therapeutics; Chief Executive Officer, Artemis Therapeutics; CEO and Director, Savara.
In numbers
- Trades disclosed
- 108
- Buys
- 10
- Sells
- 2
- Bought
- $140K
- Sold
- $1.3M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 31 Jan 2006
- Last trade
- 12 Mar 2026
- Last filed
- 12 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Mar 2026filed 12 Mar 2026 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Bought | $24K15,000 at $1.63 | filing |
| 12 Mar 2026filed 12 Mar 2026 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Bought | $24K15,000 at $1.63 | filing |
| 5 Mar 2026filed 6 Mar 2026 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,250,000 at $0.00 | filing |
| 5 Mar 2026filed 6 Mar 2026 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,250,000 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Code M | —31,250 | filing |
| 11 Feb 2026filed 13 Feb 2026 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Code F | $23K12,869 at $1.80 | filing |
| 11 Feb 2026filed 13 Feb 2026 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —31,250 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —31,250 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Code M | —31,250 | filing |
| 11 Feb 2026filed 13 Feb 2026 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Code F | $23K12,869 at $1.80 | filing |
| 19 Dec 2025filed 19 Dec 2025 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Code A | —8,925 | filing |
| 19 Dec 2025filed 19 Dec 2025 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Code F | $561334 at $1.68 | filing |
| 10 Mar 2025filed 12 Mar 2025 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,300,000 at $0.00 | filing |
| 11 Feb 2025filed 12 Feb 2025 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —31,249 at $0.00 | filing |
| 11 Feb 2025filed 12 Feb 2025 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Code M | —31,249 | filing |
| 11 Feb 2025filed 12 Feb 2025 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Code F | $8,15612,547 at $0.65 | filing |
| 21 Nov 2024filed 22 Nov 2024 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Bought | $24K40,000 at $0.60 | filing |
| 24 May 2024filed 28 May 2024 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Bought | $11K10,000 at $1.05 | filing |
| 7 Mar 2024filed 8 Mar 2024 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,900,000 at $0.00 | filing |
| 11 Feb 2024filed 12 Feb 2024 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —31,249 at $0.00 | filing |
News
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Shares Down 1.2% – What's Next?LCTX · dailypolitical.com · 17 Oct 2026
0 headlines in the last 90 days name Brian M. Culley; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.